PLoS ONE (Jan 2017)

CCL11 is increased in the CNS in chronic traumatic encephalopathy but not in Alzheimer's disease.

  • Jonathan D Cherry,
  • Thor D Stein,
  • Yorghos Tripodis,
  • Victor E Alvarez,
  • Bertrand R Huber,
  • Rhoda Au,
  • Patrick T Kiernan,
  • Daniel H Daneshvar,
  • Jesse Mez,
  • Todd M Solomon,
  • Michael L Alosco,
  • Ann C McKee

DOI
https://doi.org/10.1371/journal.pone.0185541
Journal volume & issue
Vol. 12, no. 9
p. e0185541

Abstract

Read online

CCL11, a protein previously associated with age-associated cognitive decline, is observed to be increased in the brain and cerebrospinal fluid (CSF) in chronic traumatic encephalopathy (CTE) compared to Alzheimer's disease (AD). Using a cohort of 23 deceased American football players with neuropathologically verified CTE, 50 subjects with neuropathologically diagnosed AD, and 18 non-athlete controls, CCL11 was measured with ELISA in the dorsolateral frontal cortex (DLFC) and CSF. CCL11 levels were significantly increased in the DLFC in subjects with CTE (fold change = 1.234, p < 0.050) compared to non-athlete controls and AD subjects with out a history of head trauma. This increase was also seen to correlate with years of exposure to American football (β = 0.426, p = 0.048) independent of age (β = -0.046, p = 0.824). Preliminary analyses of a subset of subjects with available post-mortem CSF showed a trend for increased CCL11 among individuals with CTE (p = 0.069) mirroring the increase in the DLFC. Furthermore, an association between CSF CCL11 levels and the number of years exposed to football (β = 0.685, p = 0.040) was observed independent of age (β = -0.103, p = 0.716). Finally, a receiver operating characteristic (ROC) curve analysis demonstrated CSF CCL11 accurately distinguished CTE subjects from non-athlete controls and AD subjects (AUC = 0.839, 95% CI 0.62-1.058, p = 0.028). Overall, the current findings provide preliminary evidence that CCL11 may be a novel target for future CTE biomarker studies.